223 related articles for article (PubMed ID: 26965184)
21. A patent review of immunoproteasome inhibitors.
Ogorevc E; Schiffrer ES; Sosič I; Gobec S
Expert Opin Ther Pat; 2018 Jul; 28(7):517-540. PubMed ID: 29865878
[TBL] [Abstract][Full Text] [Related]
22. The Functional and Mechanistic Roles of Immunoproteasome Subunits in Cancer.
Tripathi SC; Vedpathak D; Ostrin EJ
Cells; 2021 Dec; 10(12):. PubMed ID: 34944095
[TBL] [Abstract][Full Text] [Related]
23. Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.
Basler M; Maurits E; de Bruin G; Koerner J; Overkleeft HS; Groettrup M
Br J Pharmacol; 2018 Jan; 175(1):38-52. PubMed ID: 29034459
[TBL] [Abstract][Full Text] [Related]
24. Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits.
Maurits E; Degeling CG; Kisselev AF; Florea BI; Overkleeft HS
Chembiochem; 2020 Nov; 21(22):3220-3224. PubMed ID: 32598532
[TBL] [Abstract][Full Text] [Related]
25. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Citrin R; Foster JB; Teachey DT
Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Niewerth D; Jansen G; Assaraf YG; Zweegman S; Kaspers GJ; Cloos J
Drug Resist Updat; 2015 Jan; 18():18-35. PubMed ID: 25670156
[TBL] [Abstract][Full Text] [Related]
27. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
Maccari R; Ettari R; Adornato I; Naß A; Wolber G; Bitto A; Mannino F; Aliquò F; Bruno G; Nicolò F; Previti S; Grasso S; Zappalà M; Ottanà R
Bioorg Med Chem Lett; 2018 Feb; 28(3):278-283. PubMed ID: 29292224
[TBL] [Abstract][Full Text] [Related]
28. A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities.
de Bruin G; Xin BT; Kraus M; van der Stelt M; van der Marel GA; Kisselev AF; Driessen C; Florea BI; Overkleeft HS
Angew Chem Int Ed Engl; 2016 Mar; 55(13):4199-203. PubMed ID: 26511210
[TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibitors in acute leukemia.
Niewerth D; Dingjan I; Cloos J; Jansen G; Kaspers G
Expert Rev Anticancer Ther; 2013 Mar; 13(3):327-37. PubMed ID: 23477519
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Immunoproteasome-Specific Proteolytic Activity Using Fluorogenic Peptide Substrates.
Kim S; Park SH; Choi WH; Lee MJ
Immune Netw; 2022 Jun; 22(3):e28. PubMed ID: 35799704
[TBL] [Abstract][Full Text] [Related]
31. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism.
Wang J; Fang Y; Fan RA; Kirk CJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769030
[TBL] [Abstract][Full Text] [Related]
32. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
33. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome.
Basler M; Dajee M; Moll C; Groettrup M; Kirk CJ
J Immunol; 2010 Jul; 185(1):634-41. PubMed ID: 20525886
[TBL] [Abstract][Full Text] [Related]
34. Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine.
Dubiella C; Baur R; Cui H; Huber EM; Groll M
Angew Chem Int Ed Engl; 2015 Dec; 54(52):15888-91. PubMed ID: 26563572
[TBL] [Abstract][Full Text] [Related]
35. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.
Basler M; Groettrup M
Genes Immun; 2020 Nov; 21(5):273-287. PubMed ID: 32839530
[TBL] [Abstract][Full Text] [Related]
36. No prolongation of skin allograft survival by immunoproteasome inhibition in mice.
Mundt S; Basler M; Sawitzki B; Groettrup M
Mol Immunol; 2017 Aug; 88():32-37. PubMed ID: 28582644
[TBL] [Abstract][Full Text] [Related]
37. Argyrin B, a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i.
Allardyce DJ; Bell CM; Loizidou EZ
Chem Biol Drug Des; 2019 Aug; 94(2):1556-1567. PubMed ID: 31074944
[TBL] [Abstract][Full Text] [Related]
38. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.
Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S
Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901
[TBL] [Abstract][Full Text] [Related]
39. [Research progress on selective immunoproteasome inhibitors].
Kong L; Lu J; Zhu H; Zhang J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 48(6):688-694. PubMed ID: 31955545
[TBL] [Abstract][Full Text] [Related]
40. Immunoproteasome-specific inhibitors and their application.
Basler M; Groettrup M
Methods Mol Biol; 2012; 832():391-401. PubMed ID: 22350900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
